Content by The Scientist

Giovanna Prout, chief executive officer at Countable Labs, shares how Countable PCR enables unmatched sensitivity and accuracy for genomics research.

Predictive modeling platforms are helping scientists design more stable, scalable proteins for biomanufacturing and therapeutic research.

This postdoctoral researcher integrates molecular dynamics simulations and cryo-electron microscopy data to map the ensembles of proteins.

This postdoctoral researcher develops machine learning approaches to map conserved disease mechanisms across multiple organs.

This postdoctoral researcher uses mathematical modeling and computational neuroscience to discover how neural circuits navigate tight biological constraints.

Elmar Nurmemmedov from CellarisBio discusses real-time and dynamically state-resolved cell target engagement technologies for advancing drug discovery.

This postdoctoral researcher explores how cancer cells adapt their metabolism to survive therapy and overcome drug resistance in hematologic malignancies.

This postdoctoral researcher explores trained immunity and how inflammatory signals reprogram bone marrow cells to drive multiple interconnected chronic diseases.

This postdoctoral fellow develops three-dimensional human organoid models to capture complex cellular interactions and improve translational drug development.

In just a few decades, DNA sequencing technologies evolved from slow, manual processes to rapid, automated ones, making decoding the genome more accessible.

This postdoctoral fellow investigates how long non-coding RNAs regulate mitochondrial behavior in neurodegenerative disease models.

Got an appetite for trivia? Sate your hunger with this meat allergy trivia challenge.

Researchers from around the world share their favorite bacteria, viruses, and fungi, highlighting their unique abilities in space, disease, and the environment.

This postdoctoral researcher explores molecular mechanisms of drug synergy and resistance in acute myeloid leukemia using patient-derived xenograft models.

Uncontrolled antibody variables, rather than experimental design, may be driving irreproducible science.